2022 CACLP Booth No.: A4-2804

On September 28, a series of activities for the 110th anniversary of Peking University's Medical Education, "the Collective Signing Ceremony of the University-Enterprise Joint Research & Development Platform", was held. As the first enterprise to jointly establish a joint laboratory with Peking University, SANSURE Bio was invited to participate and signed a cooperation agreement with Peking University.

Qiao Jie, an academician of the Chinese Academy of Engineering, the Executive Vice President of Peking University, and the Director of the Medical Department of Peking University, said that scientific and technological innovation in the medical discipline is an important part of China's scientific and technological innovation strategy. Medical scientists and technicians should take people's health as the goal, and march toward the depth and breadth of medical science. There is still much room to promote and improve the overall medical innovation in the future. More people from the frontline who understand the frontline needs, as well as scientists who master cutting-edge science and technology, need to participate in the innovation and development of medical science and technology. At the same time, she warmly invited SANSURE to attend the 110th Anniversary Celebration Conference of Peking University Medicine, and gave her keen expectation to deepen cooperation between the two sides and jointly write a new chapter of high-quality development of higher education in the new era.

As a leading enterprise in the field of in vitro diagnostics in China, SANSURE has established a good school enterprise cooperation relationship with Peking University. The establishment of the Peking University SANSURE Joint Laboratory has integrated the existing talent advantages of Peking University and SANSURE's biological resources advantages, built an open in vitro diagnostic industry cooperation platform, not only carried out research and development of in vitro diagnostic reagents, instruments and other fields and related basic and clinical research in response to major national needs, but also explored and formed a new scientific research cooperation model of "production, learning, research and application" integration and the whole industry chain, leading the development of the industry, Promote scientific and technological innovation, and help to build a "healthy China 2030".

The PKU-SANSURE Joint Laboratory has held nearly 10 academic forums and conferences focusing on the research and development of new technologies and new materials in the fields of infectious diseases, tumors, blood safety, genetic metabolism, maternal and child health, public health, chronic diseases, and in vitro diagnosis, and has promoted the Research on Molecular Mechanisms of Cellular Immune Status of Patients with Tuberculosis and Nonnuclear Mycobacterium Infection, the Research and Development of Reagents for Detection of Non Hepatophilic Pathogens Related to Hepatitis of Unknown Cause The review, establishment and operation of more than 10 scientific research projects, including the Multi center Research on Domestic HIV Virus Nucleic Acid Detection.

In the future, the PKU SANSURE Joint Laboratory will continue to make efforts to strengthen multi-party exchanges and cooperation, cross integration, promote the transformation of scientific and technological achievements, establish a new model of high-level, high-level and highly integrated strategic cooperation between schools and enterprises, and establish a new benchmark for school enterprise cooperation that focuses on collaboration, innovation and cooperation.